CURLF · Curaleaf Holdings, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Curaleaf posted Q2 revenue of $340M (up 10% YoY) with 50% gross margin and $70M adjusted EBITDA, swung to net income of $12.5M, and guided Q3 revenue to ~$347M (low-single-digit sequential growth) amid macro caution.
- + Q2 revenue grew 10% YoY to $340M, beating guidance
- + Gross margin expanded to 50%, up 170 bps YoY
- + International revenue grew 26% YoY led by UK, Germany, Poland
- + Swung to $12.5M net income from continuing operations vs. $48M loss YoY
- − Q3 revenue guided to low-single-digit sequential growth implying ~$347M, signaling caution
- − Adjusted EBITDA margin declined to 21% (120 bps YoY) due to international drag and SG&A pressure
- − Core SG&A rose $15M YoY to $115M, pressuring leverage
- − Six-month gross margin declined 80 bps YoY to 49%
- − International gross margin fell 20 bps sequentially to 42% on German price compression
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $133.5M | Six months ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 20.1% | six months ended June 30, 2026 | — |
| Adjusted gross profit margin from continuing operations non-GAAP | 49.4% | six months ended June 30, 2026 | — |
| Free cash flow from continuing operations non-GAAP | $17.39M | Six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CURLF
this stock
Curaleaf Holdings, Inc.
|
$2.08B | — | -5.0% | — | 0.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$62.65B | +28.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.88B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$48.14B | +30.9% | +4.3% | 67.7 | 2.6% |
|
HLN
Haleon plc
|
$44.72B | +0.6% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CURLF | -10.9% | -32.2% | -20.0% | -23.4% | +4.0% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -9.7% | -31.7% | -28.1% | -24.2% | -8.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.